By

Biopharmaceutical company, Cellceutix Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as...

By

PRESS RELEASE Researchers at the University of Liverpool have demonstrated a new treatment against antibiotic resistant bacterial infections. Published in Nature Biotechnology, the study showed that...

By

For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during...

By

The Dutch company, Micreos, launched the first  bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as...

By

Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce positive top-line results...

By

An experimental drug currently being trialed for influenza and Ebola viruses could have a new target: norovirus, often known as the winter vomiting virus. A team of researchers at the University of Cambridge...

By

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, provides an update on its Ebola program. The Company is reporting it has commenced limited GMP manufacture...

By

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to...

The first case of Ebola Virus Disease (EVD) to be confirmed in the United States, Liberian man, Thomas Eric Duncan remains in critical condition. His condition is stable, according to Texas Health...

By

Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the development of AeroVanc, the first inhaled antibiotic being developed to address the growing number...